300204.SZ
舒泰神
SZSE · Healthcare · C 制造业 · CN
CNY 21.00
−5.32%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 203.9M | 220.2M | 324.8M | 364.2M | 549.0M |
| Cost of Revenue | 46.5M | 50.1M | 62.3M | 64.7M | 101.4M |
| Gross Profit | 157.4M | 170.2M | 262.5M | 299.5M | 447.5M |
| Operating Expenses | |||||
| R&D Expense | 80.7M | 84.9M | 107.1M | 412.3M | 362.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 44.5M | 42.7M | 42.0M | 66.6M | 45.4M |
| Selling & Marketing Expense | 112.8M | 121.8M | 153.9M | 181.6M | 265.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 253.2M | 261.4M | 307.3M | 663.4M | 679.0M |
| Cost and Expenses | 299.8M | 311.5M | 369.6M | 728.1M | 780.4M |
| Operating Income (EBIT) | (91.9M) | (87.4M) | (33.6M) | (366.2M) | (243.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (93.2M) | (88.3M) | (34.3M) | (366.4M) | (243.1M) |
| Income Tax Expense | (296.0K) | (216.6K) | 113.4M | 32.4M | (46.1M) |
| Bottom Line | |||||
| Net Income | (83.9M) | (77.8M) | (144.8M) | (398.9M) | (197.0M) |
| Earnings from Cont. Ops | (93.0M) | (88.1M) | (147.7M) | (398.9M) | (197.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (83.9M) | (77.8M) | (144.8M) | (398.9M) | (197.0M) |
| Per Share | |||||
| Basic EPS | (CN¥0.17) | (CN¥0.16) | (CN¥0.30) | (CN¥0.84) | (CN¥0.41) |
| Diluted EPS | (CN¥0.17) | (CN¥0.16) | (CN¥0.30) | (CN¥0.84) | (CN¥0.41) |
| Revenue Per Share | CN¥0.48 | CN¥0.45 | CN¥0.67 | CN¥0.77 | CN¥1.14 |
| Shares | |||||
| Basic Shares Outstanding | 421.6M | 486.0M | 482.8M | 474.9M | 480.5M |
| Diluted Shares Outstanding | 421.6M | 486.0M | 482.8M | 474.9M | 480.5M |
| Profitability Metrics | |||||
| EBITDA | — | (63.3M) | (10.8M) | (334.6M) | (211.4M) |
| D&A | — | 24.1M | 22.8M | 31.6M | 31.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026